Five-year data from Genentech SMA study released
SMA patients in the long-term extension Evrysdi study maintained or improved key developmental skills over the five-year period, data shows.
Source: europeanpharmaceuticalreview.com
Roche Group News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Roche Group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Roche Group Today - Breaking & Trending Today
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
Initial data from the ongoing Phase 2 trial showed a 12-month overall survival rate of 69% and a median overall survival of 17.5 months in patients with previously treated PD-L1-positive metastatic...
Source: marketscreener.com
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in
Initial data from the ongoing Phase 2 trial showed a 12-month overall survival rate of 69% and a median overall survival of 17.5 months in patients with...
Source: globenewswire.com
BioNTech SE: Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
Initial data from the ongoing Phase 2 trial showed a 12-month overall survival rate of 69% and a median overall survival of 17.5 months in patients with previously treated PD-L1-positive metastatic non-small
Source: finanznachrichten.de